ESR1 and breast carcinoma: WT161, an HDAC6 inhibitor, can sensitize luminal breast cancer more effectively than other subtypes by activating the apoptotic protein X-Linked Inhibitor of Apoptosis (XIAP) and downregulating EGFR, HER2, and ERα [217].